Anthracyclines: Review of genotoxicity and carcinogenicity studies

International Journal of Oncology

Volumn 8, Issue 3, 1996, Pages 525-536

  Mazue G ^a   Williams, G M ^b   Iatropoulos, M J ^b   Newman, A J ^a   Sammartini, U ^a   Pulci, R ^a   Castellino, S ^a   Scampini, G ^a   Brughera, M ^a   Imondi, A R ^a   Podesta A ^a  

^a PFIZER INC   (United States)

^b AMERICAN HEALTH FOUNDATION   (United States)

Author keywords

Anthracyclines; Doxorubicin; Epirubicin; Genotoxicity; Idarubicin

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DOXORUBICIN; EPIRUBICIN; IDARUBICIN;

ANIMAL EXPERIMENT; ARTICLE; CARCINOGENICITY; DRUG TOXICITY; GENOTOXICITY; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0029989659     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Mazué G, Iatropoulos M, Imondi A, Castellino S, Brughera M, Podestà A, Della Torre P and Moneta D: Anthracyclines: A review of general and special toxicity studies. Int J Oncol 7: 713-726, 1995.
2. Williams GM: Methods of evaluating chemical genotoxicity. Annu Rev Pharmacol Toxicol 29: 189-211, 1989.
3. Williams GM and Weisburger JH: Chemical carcinogenesis. In: Casarett and Doull's Toxicology: The Basic Science of Poisons. Amdur MO, Doull J and Klaassen CD (eds.). Pergamon Press, NY, 4th edit, pp127-200, 1991.
4. Maron DM and Ames BN: Revised methods for the Salmonella mutagenicity test. Mutat Res 113: 173-215, 1983.
5. Jensen DA: In: Handbook of Mutagenicity Test Procedures. Kilbey BJ, Legator M, Nichols W and Ravel C (eds). Elsevier Science Publisher, Amsterdam, pp269-290, 1984.
6. Preston RJ, San Sebastian JR and McFee AF: The in vitro human lymphocyte assay for assessing the clastogenicity of chemical agents. Mutat Res 189: 175-183, 1987.
7. Preston RJBJ, Galloway S, Holden H, McFee AF and Shelby M: Mammalian in vivo cytogenetic assays: Analysis of chromosome aberration in bone marrow cells. Mutat Res 189: 157-165, 1987.
8. Cardy RH: Sexual dimorphism of the normal rat mammary gland. Vet Pathol 28: 139-145, 1991.
9. Grandi M, Giuliani FC, Verhoef V, Filppi J: Preclinical procedures for evaluation of new anthracyclines: Screening of anthracycline analogs. In: Anthracycline and Anthracenedione based Anticancer Agents. Lown JW (ed). Elsevier Science Publisher, vol 6, Amsterdam, pp571-594, 1988.
10. Belvedere G, Suarato A, Geroni C, Giuliani FC and D'Incalci M: Comparison of intracellular drug retention DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo). Biochem Pharmacol 38: 3713-3721, 1989.
11. Grandi M, Pezzoni G, Ballinari D, Capolongo Ll, Suarato A, Bargiotti A, Faiardi D and Spreafico F: Novel anthracycline analogs. Cancer Treatment Rev 17: 133-138, 1990.
12. Facchetti I, Grandi M, Cucchi P, Geroni C, Penco S and Vigevani A: Influence of lipophilicity on cytotoxicity of anthracyclines in LoVo and LoVo/Dx human cell lines. Anti-Cancer Drug Des 6: 385-397, 1991.
13. Ferguson LR and Baguley BC: Topoisomerase II enzymes and mutagenicity. Environ Mol Mutagen 24: 245-261, 1994.
14. Marselos M and Vainio H: Carcinogenic properties of pharmaceutical agents evaluated in the IARC monographs programme. Carcinogenesis 12: 1751-1766, 1991.
15. Ishidate M, Harnois MC and Sofumi T: A comparative analysis of data on the clastogenicity of 951 chemical substances tested in mammalian cell cultures. Mutat Res 195: 151-213, 1988.
16. International Agency for Reasearch on Cancer: IARC monographs on the carcinogenic risk of chemicals to humans. Overall evaluation of carcinogenicity: An updating of IARC monographs. Suppl 7. International Agency for Research on Cancer, Lyon, France, vol 1 to 42, 1987.
17. Williams GM and Weisburger JH: Systematic carcinogen testing through the decision point approach. Annu Rev Pharmacol Toxicol 21: 393-416, 1981.
18. Russo J, Russo IH, Rogers AE, van Zwieten MJ and Gusterson B: 'Tumours of the mammary gland'. In: Pathology of Tumours in Laboratory Animals. Turusov VS and Mohr U (eds). 2nd edition. International Agency for Research on Cancer, Lyon, France pp47-78, 1990.
19. Boorman GA, Wilson JT, van Zwieten MJ and Eustis LE: 'Mammary gland'. In: Pathology of the Fischer Rat. Boorman GA, Eustis LE, Elwell RE, Montgomery CA and MacKenzie WF (eds). Chapter 19, Academic Press, pp295-313, 1990.
20. Carlton WW, Ernst H, Faccini JM, Greaves P, Krinke GJ, Long PH, Maekawa A, Newsholme SJ and Weisse G: In: Fascicle 2. Soft Tissue and Musculoskeletal System of 'International Classification of Rodent Tumours'. Mohr U (ed). IARC Scientific Publications, pp12, 1992.
21. Weisburger JH, Griswold DP, Presjean JD, Casey AE, Wood HB and Weisburger EK: The carcinogenic properties of some of the principal drugs used in clinical cancer chemotherapy. In: Recent Results in Cancer Research. Grundmann E, Gross R (eds). Vol. 52, Springer-Verlag, Berlin, pp1017, 1975.
22. Williams GM: Definition of a human cancer hazard. In: Nongenotoxic Mechanisms in Carcinogenesis. Banbury Report 25, Cold Spring Harbor Laboratory, New York, pp367-380, 1987.
23. Bucciarelli E, Provvidenza M, Testarella M and Miele-Bianco F: Lack of oncogenic activity of doxorubicin and daunorubicin in Balb/C mice. Tumori 68: 1-3, 1982.
24. Sammartini U: Long-term toxicity study of doxorubicin and other antitumoral compounds in female rats (7 weeks old) after a single intravenous injection followed by a 12-month recovery period. Pharmacia Internal Report, July, 1995.
25. Sammartini U: Long-term toxicity study of doxorubicin and other antitumoral compounds in female rats (13 weeks old) a single intravenous injection followed by a 12-month recovery period. Pharmacia Internal Report, June, 1995.
26. Bertazzoli C, Chieli T and Solcia E: Different incidence of breast carcinoma or fibroadenomas in daunomycin or adriamycin treated rats. Experientia 27: 1209-1210, 1971.
27. Solcia E, Ballerini L, Bellini O, Sala L and Bertazzoli C: Mammary tumors induced in rats by adriamycin and daunomycin. Cancer Res 38: 1444-1446, 1978.
28. Marquardt H, Philips FS and Sternberg SS: Tumorigenicity in vivo and induction of malignant transformation and mutagenesis in cell cultures by adriamycin and daunomycin. Cancer Res 36: 2065-2069, 1976.
29. Bucciarelli E, Provvidenza M, Santori P and Vespasiani G: Oncogenesi da adriamicina e daunomicina in ratti maschi e femmina Sprague Dawley. Dati preliminari. Lav Ist Anat Istol Patol Perugia 38: 71-81, 1978.
30. Bucciarelli E: Mammary tumor induction in male and female Sprague Dawley rats by adriamycin and daunomycin. J Natl Cancer Inst 66: 81-84, 1981.
31. Sammartini U and Costa R: Long-term toxicity study of doxorubicin, epirubicin and idarubicin given intravenously to rats every three weeks for ten cycles. Pharmacia Internal Report, February, 1996.
32. Casazza A, Bellini O, Formelli F, Giuliani F, Lenaz L and Magrini V: Tumors and dental ocular abnormalities after treatment of infant rats with adriamycin. Tumori 63: 331-338, 1977.